Abstract
Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have